Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T.
Aviles-Olmos I, et al. Among authors: kahan j.
J Parkinsons Dis. 2014;4(3):337-44. doi: 10.3233/JPD-140364.
J Parkinsons Dis. 2014.
PMID: 24662192
Free article.
Clinical Trial.